|
Patent landscape, scope, and claims: |
Scope and Claim Coverage of US Drug Patent 12,171,739 (Formula I Compound Claims)
US 12,171,739 is drafted as a broad structure-of-Formula I patent with claim 1 covering a very large chemical space: an A-position heteroatom system (A = O, C(═O), S, SO, SO2), a fused 6-membered heteroaryl core (B = fused 6-membered heteroaryl ring), and extensive latitude across substituents E, D1-D10, R1, R2, R3, R6, R7, R8, R8a, R8b, R9, R10, R12, R13, R14, R15-R20 and other variables with multiple ring-forming alternatives. Dependent claims narrow to specific parameter combinations, then to specific E/R3 selections and exemplified substituents. The resulting enforceable scope is “class-of-structures” with limited functional language; infringement turns on whether a target compound fits the Formula I variable assignments and ring-closure definitions.
What does US 12,171,739 claim: a compound Formula I or specific drug product?
Answer: It claims compounds and salts that satisfy Formula I, plus compositions and a process step. It is not limited to a single active ingredient embodiment, dose form, or route in the provided claim set.
Claim 1: Structure-of-Formula I compound coverage
Claim 1 covers “a compound of Formula I or a pharmaceutically acceptable salt thereof,” then defines the structure using a large matrix of variables. Key structural anchors are:
- A at a defined position: O, C(═O), S, SO, or SO2
- G fixed as N
- B as a fused 6-membered heteroaryl ring
- E is defined via variable X and tautomers:
- Includes a constraint: X is N or CH
- Core heteroatom patterning on the fused system and adjacent rings via D1–D10, with multiple “independently N or CR19” definitions and at least one “not CR19” and at least one “is N” conditions.
- Variable substituent plenitude across:
- R1: H or alkyl
- R2: very broad; includes halogens and multiple carbonyl/sulfonamide/sulfonyl/alkoxy/aryl/heteroaryl/cycloalkyl options plus optional substitution on those rings
- R3: broad substituent class including halogens, cyano, nitro, alkyl chains, heteroalkyl fragments, and extensive heterocyclic ring substitutes
- R6/R7/R8/R9/R10/R12/R13/R14/R15-R20: each has broad optional substituent language, ring-closure alternatives, and heteroatom content rules
- Ring-formation logic:
- Several sections explicitly state: “R8 and R8a together with the atom … form a 3 to 6 membered carbocyclic ring,” and similar ring closures for other variable pairs.
Claim 2–3: parameter narrowing
- Claim 2: “each R3 is independently Q, Z, halogen, cyano, nitro, …” and expands that Z and R15/R16/R17 and Ra/Rb/Rc are within narrower sets. It tightens the types of R3 substituents and standardizes R-group families for the R3-position embodiments.
- Claim 3: a specific selection:
- G is N (already stated in claim 1)
- A is O or S (explicit restriction of A to oxygen or sulfur).
Claim 4–9: E selection becomes the first major “claim funnel”
The provided text shows claim 4 as dependent on claim 1 with E selected from… but the exact structures are not fully rendered in the text you supplied. Claims 5–9 then point to:
- Claim 5: E selected from specific structures (with k = 0–3)
- Claim 6–9: additional E-specific restrictions, including “each R12 and each R19 group is independent of the other” (claim 8) and further E sets (claims 7–9).
Practical effect: even if E definitions are complex, each dependent claim typically reduces the set of compounds that infringe claim 1 by enforcing specific E-scaffold choices.
Claims 10–12: m = 1 and R3 is Z, then Z is constrained
- Claim 10: m is 1 and R3 is Z
- Claim 11: Z constrained and W/V constraints:
- “Z is selected from … in which W is O or S; W2 is O or S; and V is CR8R9”
- Claim 12: R6 and R8 definitions narrow R6 and the substitutions:
- R6 is H or C1–C6 alkyl
- R8 and R8a are H or C1–C6 alkyl optionally substituted with ORa
- ORa is H or C1–C6 alkyl
- or R8 and R8a together form a C3–C6 cycloalkyl ring
This dependent lineage can materially change infringement outcomes because it removes large portions of the R3/R8 universe.
Claims 13–14: additional R3 subtype constraints
- Claim 13: m = 1 and R3 is selected from specific structures (not fully visible in the text)
- Claim 14: m is 1 and R3 is OR15 (first clear “functional handle” at R3 as an ether linkage)
Claims 15–16: R3 = OR15 mapped to enumerated classes
- Claim 15: R3 (via OR15) is constrained to:
- (i) hydrogen on R15
- (ii) cycloalkyl/alkoxy variants, including cyclopentanoxy and cyclohexanoxy class patterns
- (iii) cycloalkylalkyl
- (iv) C1–C6 alkyl optionally substituted with a defined set of hetero/sulfonyl/carbonyl functionalities
- (v) heterocyclic rings (5–6 membered; N/O; with limited optional substitution)
- (vi) heterocyclylalkyl (5–6 membered; N/O)
- (vii) heteroaryl (5–6 membered; 1–3 N)
- (viii) heteroarylalkyl (5–6 membered; 1–2 N)
- Claim 16: further examples for R3 OR15 including:
- OH; multiple alkoxy chain examples
- “2-methylpyridin-4-yloxy” and “2-chloropyridin-4-yloxy” class patterns
- extensive list of protected/extended alkoxy and sulfonyl-containing ether/sulfonate-like entities
- these read as concrete embodiment sets that can anchor validity and infringement for specific analogs.
Claims 17–19: R3 expanded into special substituent classes and named ionic/salt-like groups
- Claim 17: with m = 1 and R3 selected from:
- (i) heterocycles with N/O and limited substitution
- (ii) heteroaryl rings linked by ring nitrogen atom
- (iii) amide-like substituents: “—NR15C(O)R16”
- (iv) urea-like/amide-like: “—C(═O)NR15R16”
- (v) SO2R15 and (vi) SOR15 and (vii) SR15 classes
- (viii) halogen
- (ix) —CO2R15
- (x) C1–C6 alkyl optionally substituted with OR15
- (xi) alkynyl with OR15 or heterocycle-bearing variants
- (xii) —NR15C(O)NR16R17
- (xiii) heterocyclylalkyl (6-membered; ring N; optional second heteroatom)
- Claim 18: enumerates specific R3 selections including:
- 1H-pyrazol-1-yl
- multiple amino-acyl substituents (C(O)NH motifs)
- morpholine/amide/acyl patterns
- explicit counterion/salt-like embodiments:
- “4-methylbenzenesulfonate, ethanesulfonate”
- “ethysulfinyl; EtS—”
- bromo
- these embodiments increase the likelihood that real-world marketed salts/derivatives can be captured if they map into R3 substituent categories.
- Claim 19: defines additional narrowing:
- E set includes (implicitly) constrained E
- j is 0 or 1
- R19 is H, C1–C6 alkyl, or halogen
- R20 is H
- plus an explicit exclusion:
- “provided that R3 … is not NR15C(═O)(CH═CH)R16a …”
- This is a meaningful carve-out that may preserve patentability against at least one structural family.
Claim 20–21: compositions
- Claim 20: composition comprising compound of claim 1 (or pharmaceutically acceptable salt) + pharmaceutically acceptable carrier
- Claim 21: composition with compound + pharmaceutically acceptable diluent or carrier
These are standard generic formulation composition claims and generally do not provide narrow product exclusivity unless paired with manufacturing/process or method-of-use claims (not shown here).
Claim 22: method of preparing the Formula I compound
- “A method of preparing a compound of Formula I … comprising: (a) reacting a compound of formula (F1) with a compound of formula (F2) … Z represents a leaving atom or group.”
This is a process claim framed around F1-F2 coupling with a leaving-group handle. Without the identity of F1 and F2 in your text, the claim scope remains generic at the level of “a coupling step using a Z-leaving atom,” but it still matters for generic manufacturing freedom-to-operate and for process-based infringement theories.
How broad is the claim scope in chemical space?
Answer: Claim 1 is extremely broad at the “structure class” level because multiple variable families use open-ended “independently selected” lists plus optional substitution on rings.
Breadth drivers
- Core acceptance criteria are few and structural
- A only has 5 discrete options
- G is fixed as N
- B is a fused 6-membered heteroaryl ring
- Substituent universes are open-ended
- R2, R3, R12, R19, and R20 are each “independently” drawn from large lists containing:
- halogen/cyano/nitro
- carbonyls (C(O), C(O)O, OC(O))
- sulfonamides/sulfones (SO2NR, S(O)p(alkyl), SO2R)
- alkoxy and heteroaryl substituents
- multiple ring systems including heteroaryl/heterocyclyl and their alkylated variants
- Ring-closure alternatives multiply accessible structures
- Several variable pairs can cyclize to form rings (3–10 members for some closures).
- Dependent claims still cover large subsets
- Even “narrow” dependent claims (e.g., m = 1 and R3 = OR15) still list multiple ring classes and functional group variants.
Where scope is constrained
Scope narrows through:
- conditional “at least one of D4 and D5 is not CR19” and “at least one of D7–D10 is N”
- defined ranges for j, m, n, q, p
- specific E selections and specific R3 subtype families in later dependents
- a targeted carve-out in claim 19 excluding at least one amide-like vinylated family.
What specific claim limitations are most likely to decide infringement?
Answer: In practice, infringement will hinge on (1) the Formula I scaffold identity, (2) the A/G/B/E region definitions, and (3) the substituent mapping at R3 (because later dependents tie R3 tightly to enumerated classes).
Most decisive structural checkpoints
- A position: O vs C(═O) vs S vs SO vs SO2 (claim 3 is particularly decisive at A = O or S)
- E/X definition: whether X is N or CH and which E structure family is used (claims 4–9)
- m and R3 relationship: several dependents require m = 1
- R3 class:
- R3 = Z (claim 10–12 family)
- R3 = OR15 (claim 14–16 family)
- R3 among heterocycle/amide/sulfonamide/sulfoxide/thioether and named salts (claim 17–18)
- Exclusion: claim 19 excludes a vinylated acyl/amide family at R3.
If a competitor’s compound maps to a different scaffold at E/X, or fails the ring definitions for B and D1–D10, it can fall outside even if the substituent types resemble claim 1.
What formulations or salts does US 12,171,739 cover?
Answer: The patent covers pharmaceutically acceptable salts of Formula I compounds via claim 1 and composition claims (claims 20–21). It also enumerates particular ionic-like R3 substituents in claim 18 (examples include “4-methylbenzenesulfonate” and “ethanesulfonate”), which can align with common salt forms.
Salt/ionic coverage in the provided dependent text
- Claim 18 explicitly lists sulfonate-like forms:
- 4-methylbenzenesulfonate (tosylate-like)
- ethanesulfonate (mesylate-like)
- Claim 18 also lists “Br” and sulfur-containing groups (“ethysulfinyl; EtS—”), which may map to counterion or specific substituent categories depending on how the patent defines R3/ionic association in Formula I.
Is there process protection: what does claim 22 protect?
Answer: Claim 22 protects a preparation step that couples two intermediates, F1 and F2, where F2 has a leaving group “Z.”
Process claim scope (as provided)
- React F1 + F2 (Z = leaving atom/group)
- The claim does not, in your excerpt, define:
- catalysts
- solvents
- temperatures
- purification steps
- stereochemical controls
So the enforceable scope in practice depends on how F1 and F2 are defined in the specification and any more detailed dependents (not included in your excerpt).
What patent landscape issues follow from this claim drafting style?
Answer: Given the breadth of claim 1 and the funnels in dependents, US 12,171,739 likely functions as:
- a core composition-of-structures patent (claim 1)
- with follow-on narrowing handles to cover specific marketed-like variants (claims 14–18)
- plus a composition safety net (claims 20–21)
- and a manufacturing coupling step (claim 22)
High-probability landscape dynamics
- Design-around risk is mitigated by the breadth of substituent definitions, but not eliminated because the scaffold and core heteroatom/ring rules remain fixed by Formula I.
- Multiple value “entry points” exist for future licensing or litigation:
- E-specific dependents
- m=1 and OR15 dependents
- salt-like R3 enumerations in claim 18
- exclusion carve-outs in claim 19 that can be litigated as scope clarifiers.
Key Takeaways
- US 12,171,739 claim 1 is a broad Formula I “class” claim covering salts of compounds that satisfy a fused heteroaryl core (B), fixed G = N, and an A position with 5 heteroatom/functional options.
- Enforceability will turn on whether an accused compound fits the Formula I variable framework, especially E/X, the D1–D10 heteroatom constraints, and substituent mapping at R3.
- Dependent claims create infringement “funnels”:
- m = 1 and R3 = Z (claims 10–12)
- m = 1 and R3 = OR15 (claims 14–16)
- R3 enumerated to specific heterocycles/amides/sulfur moieties and salt-like groups (claims 17–18)
- Claim 19 includes an explicit R3 exclusion for a specific vinylated amide-like family.
- Claims 20–21 cover pharmaceutical compositions with carriers/diluents.
- Claim 22 adds a manufacturing/process hook for coupling F1 and F2 with a leaving group Z, but the actionable scope depends on the specific identity of F1 and F2 in the full patent document.
FAQs
-
Does US 12,171,739 cover methods of treatment or only compounds and compositions?
Only compound, salt, composition, and preparation-step language is shown in the provided claims; no method-of-use claim text is included.
-
Which parts of Formula I are most likely fixed and least design-around friendly?
The scaffold-defining elements in claim 1: A (limited set), G = N, B (fused 6-membered heteroaryl), X definition, and D1–D10 heteroatom constraints.
-
If a competitor changes only the R-group substituents, can it still avoid infringement?
It can avoid only if the modified structure falls outside the Formula I variable limits or outside specific dependent claim funnels (E selection, m/R3 relationship, or enumerated R3 sets).
-
Do the dependent claims meaningfully narrow claim 1 or just provide alternative coverage?
They narrow by constraining parameters (e.g., A = O/S, m = 1, R3 = OR15 or Z, and specific R3 enumerations) and by adding exclusions (claim 19).
-
How does claim 22 affect generic manufacturing clearance?
It can be asserted against manufacturing routes that perform the same F1–F2 coupling with a leaving-group F2; route differences that avoid that coupling step or use different core intermediates may reduce process-infringement risk.
References (APA)
- US Patent 12,171,739.
More… ↓
⤷ Start Trial
|
